Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer

International Journal of Cancer

Volumn 111, Issue 2, 2004, Pages 303-309

  Bauerschmitz, Gerd J ^a,b   Kanerva, Anna ^a,c,d   Wang, Minghui ^a   Herrmann, Isabell ^b   Shaw, Denise R ^a   Strong, Theresa V ^a   Desmond, Renee ^e   Rein, Daniel T ^a   Dall, Peter ^b   Curiel, David T ^a   Hemminki, Akseli ^a,c,d,f  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Department of Oncology   (Finland)

Author keywords

Adenovirus; Biologic therapy; Cervical cancer; Conditionally replicating adenovirus; Gene therapy; Oncolytic; Peripheral blood mononuclear cells; Virus replication

Indexed keywords

ADENOVIRUS 5 DELTA24 ARGINYLGLYCYLASPARTIC ACID; ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PROTEIN P16; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; COXSACKIE VIRUS; CYTOLYSIS; DISEASE RESISTANCE; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MICE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

EID: 3142740855     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20217     Document Type: Article

References (52)

1. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge, JO. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002;84:115-9.
2. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int J Oncol 2002;21:1161-74.
3. Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A, Kirino, T, Hamada, H. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res 1999;59:3411-6.
4. Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? BioDrugs 2002;16:77-87.
5. Suzuki K, Fueyo J, Krasnykh V, Reynolds P, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
6. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
7. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
8. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kim D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
9. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
10. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
11. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
12. Sheu JR, Lin CH, Peng HC, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits human cervical carcinoma (HeLa) cell-substratum adhesion through an RGD-dependent mechanism. Peptides 1994;15:1391-8.
13. Kawaguchi M, Hosotani R, Ohishi S, Fujii N, Tulachan SS, Koizumi M, Toyoda E, Masui T, Nakajima S, Tsuji S, Ida J, Fujimoto K, Wada M, et al. A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf=V-) is the potent inhibitor of angiogenesis. Biochem Biophys Res Commun 2001;288:711-7.
14. Hemminki A, Zinn KR, Liu B, Chaudhuri TR, Desmond RA, Rogers BE, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002;94:741-9.
15. Grill J, Van Beusechem VW, Van Der Valk P, Dirven CM, Leonhart A, Pherai DS, Haisma HJ, Pinedo HM, Curiel DT, Gerritsen WR. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res 2001;7:641-50.
16. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther 2001;8:969-76.
17. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002;13:613-26.
18. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem 2002;13:561-70.
19. Valea FA, Haskill S, Moore DH, Fowler WC Jr. Immunohistochemical analysis of alpha 1-integrins in cervical cancer. Am J Obstet Gynecol 1995;173(3 Pt 1):808-13.
20. Hughes DE, Rebello G, al-Nafussi A. Integrin expression in squamous neoplasia of the cervix. J Pathol 1994;173:97-104.
21. Chattopadhyay N, Ray S, Biswas N, Chatterjee A. Effect of all-trans-retinoic acid on integrin receptors of human cervical cancer (SiHa) cells. Gynecol Oncol 1999;75:215-21.
22. Chattopadhyay N, Chatterjee A. Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues. J Exp Clin Cancer Res 2001;20:269-75.
23. Chatterjee N, Chatterjee A. Role of alphavbeta3 integrin receptor in the invasive potential of human cervical cancer (SiHa) cells. J Environ Pathol Toxicol Oncol 2001;20:211-21.
24. Chattopadhyay N, Mitra A, Frei E, Chatterjee A. Human cervical tumor cell (SiHa) surface alphavbeta3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol 2001;127:653-8.
25. Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA, Shaw DR, Alvarez RD, Curiel DT, Strong TV. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther 2000;11:1657-69.
26. Suzuki KAR, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Can Res 2002;8:3348-59.
27. Bauerschmitz GJ, Lato JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002;62:1266-70.
28. Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel, DT, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223-31.
29. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez, RD, Siegal GP, Curiel DT, Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
30. Hemminki, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond, RA, Keriel A, Barnett B, Baker HJ, Siegal GP, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003; 7:163-73.
31. Grover CB Jr. Disorders of neutrophil production/leukopenia. In: Bennett JCPF, ed. Cecil textbook of medicine. vol. 20. Philapelphia, PA: W.B. Saunders, 1996. 908-15.
32. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-92.
33. Rein DT, Kurbacher CM. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs 2001;12:787-95.
34. Ip SM, Huang TG, Yeung WS, Ngan HY. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 2001;37:2475-83.
35. Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, Faha B. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000; 2:485-95.
36. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000;74:6147-55.
37. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-72.
38. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001;3:28-35.
39. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000;81(Pt 11):2605-9.
40. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kim D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8:746-59.
41. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kim D. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8:1618-26.
42. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
43. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987;156:107-21.
44. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom WN. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999;10:579-90.
45. Hemminki AWM, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002;13:1505-14.
46. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, Kovesdi I, Segal DM. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997;71:7663-9.
47. Goossens PH, Havenga MJ, Pieterman E, Lemckert AA, Breedveld FC, Bout A, Huizinga TW. Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum 2001;44:570-7.
48. Schranz V, Kulcsar G, Dan P, Horvath J, Nasz I, Barinsky IF, Ugryumov EP, et al. Interaction of human lymphocytes and viruses in vitro. Acta Microbiol Acad Sci Hung 1979;26:1-9.
49. Chen Z, Ahonen M, Hamalainen H, Bergelson JM, Kahari VM, Lahesmaa R. High-efficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors. J Immunol Methods 2002;260:79-89.
50. Conron M, Bondeson J, Pantelidis P, Beynon HL, Feldmann M, duBois RM, Foxwell BM. Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways. Am J Respir Cell Mol Biol 2001;25:141-9.
51. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 2002;13:129-41.
52. Horvath J, Kulcsar G, Ugryumov JP, Das P, Nasz I, Barinsky IF, Simon G, Ongradi J. Effect of adenovirus infection on human peripheral lymphocytes. Acta Microbiol Hung 1983;30:203-9.